⚠️ For Research Purposes Only — This article discusses KPV strictly as a laboratory research compound. It is not a drug recommendation, dosage guide, or medical advice. KPV is not for human consumption. It is not intended to diagnose, treat, cure, or prevent any disease. All claims below refer to published preclinical research, in vitro investigations, or peer-reviewed literature cited for scientific context only.
Introduction
KPV is a tripeptide composed of lysine, proline, and valine, corresponding to residues 11-13 of α-melanocyte-stimulating hormone (α-MSH). Its research significance stems from a notable observation: the full α-MSH tridecapeptide (Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val) exhibits potent anti-inflammatory activity, and remarkably, much of this activity is retained by the C-terminal tripeptide KPV alone — even though KPV lacks the His-Phe-Arg-Trp core pharmacophore required for binding the classical melanocortin receptors (MC1R, MC3R, MC4R, MC5R) [1][2][3].
This separation of anti-inflammatory activity from melanocortin receptor binding has made KPV a scientifically interesting research tool. It offers a way to probe α-MSH-like anti-inflammatory effects without concurrent pigmentary activity at MC1R, which has historically been considered a limitation of full-length α-MSH as a research or pharmaceutical candidate [1][2]. This article reviews KPV’s structure, mechanisms, and the principal research areas in which it has been studied: inflammatory bowel disease research, airway inflammation, wound healing, and targeted nanoparticle delivery systems.
Molecular Structure and Biochemistry
KPV is a simple tripeptide with the sequence H-Lys-Pro-Val-OH (or H-Lys-Pro-Val-NH2 in the amidated research form, corresponding to the native C-terminus of α-MSH). Its molecular formula is C16H30N4O4 (free acid) or C16H31N5O3 (amide), with a molecular mass of approximately 342 Da (free acid). For a peptide research compound, KPV is notably small and chemically simple:
- Three residues, one proline: The central proline imposes a conformational constraint that distinguishes KPV from linear flexible tripeptides. This constraint is likely important for its biological activity and has been exploited in structure-activity research.
- Basic N-terminus: The lysine ε-amino group provides a positive charge at physiological pH and is the site of reductive alkylation in the 2018 glycomimetic modification research from the Macnaughtan laboratory [11].
- Hydrophobic C-terminus: The valine at the C-terminus contributes hydrophobicity and contributes to interaction with target proteins or uptake transporters.
- Oral bioavailability: A distinguishing research feature of KPV is that it is a substrate for PepT1, the intestinal di/tripeptide transporter, which is induced in inflamed colonic tissue during inflammatory bowel disease research models. This enables orally administered KPV to be absorbed by colonic enterocytes at the site of inflammation, a mechanism characterized in detail by the Merlin laboratory [4].
- CKPV2 dimer: A disulfide-linked dimer form composed of two KPV sequences bridged by Cys-Cys ([CKPV]2) has been developed and investigated in research as a more potent anti-endotoxin variant [12].
KPV’s simplicity has both advantages and disadvantages for research. On the positive side, it is inexpensive to synthesize, chemically stable, water-soluble, and amenable to multiple delivery formats. On the negative side, its short length makes it susceptible to rapid clearance in vivo, and its mechanism of action at the receptor level is less straightforward than that of full-length α-MSH.
Mechanism of Action in Research Models
KPV’s mechanism of action has been an active research question for two decades, and the published literature describes several non-mutually-exclusive pathways.
1. NF-κB suppression. The most consistent mechanistic thread in the published research literature is that KPV inhibits NF-κB signaling in both intestinal epithelial cells and immune cells. In Caco2-BBE, HT29-Cl.19A, and Jurkat T cells, nanomolar KPV concentrations inhibited activation of NF-κB, reduced expression of pro-inflammatory cytokines, and attenuated MAP kinase signaling pathways in response to pro-inflammatory stimuli [4]. In human bronchial epithelial cells (16HBE14o-), KPV inhibited TNF-α-evoked NF-κB activation, I-κB-α stabilization, and nuclear translocation of YFP-tagged p65RelA, with evidence suggesting an interaction with the Imp-α3 binding site on p65RelA that blocks its nuclear import [8].
2. PepT1-mediated uptake. The 2008 Gastroenterology paper from the Merlin laboratory established that KPV enters intestinal epithelial cells and immune cells via PepT1, a di/tripeptide transporter that is constitutively expressed in the small intestine and inducibly expressed in inflamed colon [4]. This mechanism has two important implications for research: (a) it provides a rational basis for oral delivery of KPV in IBD research models, and (b) it introduces a target-tissue enrichment mechanism (PepT1 upregulation at sites of inflammation) that may contribute to KPV’s favorable therapeutic index in research settings.
3. MC1R-independent activity. A consistent finding in the KPV research literature is that its anti-inflammatory effects do not strictly require MC1R or other melanocortin receptors. In DSS colitis experiments using mice that express a non-functional MC1R (MC1Re/e), KPV treatment still rescued animals from colitis mortality, demonstrating that at least part of its activity is MC1R-independent [3]. Other reports have implicated MC3R (particularly in airway epithelium research [8]) as a possible contributor to KPV-like effects.
4. Nitric oxide pathway modulation. In a rabbit corneal epithelial wound healing research model, KPV accelerated re-epithelialization, and this effect was blocked by the nitric oxide synthase inhibitor L-NAME, suggesting that NO is a downstream mediator of KPV’s reparative effects in corneal research [6]. This is mechanistically distinct from the NF-κB-centric pathway described in intestinal and airway research.
5. Antimicrobial activity. α-MSH and KPV have direct antimicrobial effects against S. aureus and C. albicans in culture, independent of their immunomodulatory actions [10]. This activity may contribute to their effects in research models where infection and inflammation coexist.
Key Research Areas
1. Inflammatory Bowel Disease Research
The inflammatory bowel disease research area is where KPV has been most thoroughly characterized, with multiple independent groups contributing reproducible findings across different colitis research models.
The foundational 2008 study by Kannengiesser and colleagues demonstrated that KPV had significant anti-inflammatory effects in two well-described murine IBD research models: dextran sodium sulfate (DSS) colitis and CD45RBhi T-cell transfer colitis [3]. In the DSS model, KPV-treated mice showed earlier recovery, stronger regain of body weight, and reduced inflammatory infiltrates with significantly lower myeloperoxidase (MPO) activity in colonic tissue. In the transfer colitis model, KPV produced comparable benefits. Importantly, in MC1R-nonfunctional mice (MC1Re/e), KPV rescued all animals from DSS-induced mortality, establishing the partial MC1R-independence of its effects [3].
The Merlin laboratory followed this with a landmark 2008 Gastroenterology paper identifying PepT1 as the transporter responsible for KPV uptake in colonocytes and immune cells [4]. The same group then developed polymeric nanoparticle delivery systems to target KPV specifically to inflamed colonic tissue, reporting in a 2010 Gastroenterology paper that alginate/chitosan-encapsulated KPV-loaded NPs protected mice against DSS colitis with KPV doses 12,000-fold lower than free KPV while retaining therapeutic efficacy [5].
This nanoparticle-delivery line of research has continued: a 2017 paper in Molecular Therapy described hyaluronic acid-functionalized KPV-loaded nanoparticles (HA-KPV-NPs, ~272 nm particle size) that targeted colonic epithelial cells and macrophages, accelerated mucosal healing, downregulated TNF-α, and exhibited greater therapeutic efficacy in ulcerative colitis research models than conventional KPV-NP formulations [9]. Together, these studies make KPV one of the better-characterized peptide anti-inflammatory research tools for the IBD field, with both mechanistic and delivery-system work underpinning the molecular interest.
2. Airway Inflammation Research
Airway inflammation research is a second substantial KPV research area. The 2012 Land et al. paper in the International Journal of Physiology, Pathophysiology and Pharmacology characterized the effects of KPV and γ-MSH in immortalized human bronchial epithelial cells (16HBE14o-) exposed to TNF-α and rhinosyncitial virus as research models of airway inflammation [8]. KPV produced dose-dependent inhibition of NF-κB activation, matrix metalloproteinase-9 activity, IL-8 secretion, and eotaxin secretion.
Mechanistically, the paper demonstrated that KPV’s effects in airway epithelium were associated with its nuclear import, I-κB-α stabilization, and suppressed nuclear translocation of p65RelA. Competition assays implicated an interaction between KPV and the Imp-α3 binding site on p65RelA, potentially blocking the armadillo domain 7 and 8 of importin-α that normally recognizes the NF-κB nuclear localization signal [8]. In contrast, γ-MSH required MC3R for its anti-inflammatory effect in the same research model — highlighting that KPV and related melanocortin-derived peptides can act through distinct mechanisms even when their phenotypic outputs overlap.
This work has been cited in allergic-airway research contexts where α-MSH and its derivatives have been investigated for their effects on allergen-specific IgE production, eosinophil influx, and IL-4 production in murine models [7].
3. Wound Healing and Anti-Microbial Research
A third KPV research area concerns its effects on tissue repair and antimicrobial defense. The 2006 paper by Bonfiglio et al. in Experimental Eye Research demonstrated that topical KPV accelerated corneal epithelial wound healing in a rabbit research model of mechanical abrasion [6]. Sixty hours after treatment, 100% of corneas treated with KPV (or the NO donor sodium nitroprusside) were completely re-epithelialized, compared with none of the vehicle-treated controls. The effect was blocked by L-NAME, implicating NO as a downstream mediator [6].
On the antimicrobial side, the 2000 study by Cutuli and colleagues reported that α-MSH and KPV inhibited S. aureus colony formation and reduced viability and germ tube formation of C. albicans [10]. These effects occurred over a broad concentration range including the physiological picomolar range, and were attributed at least in part to the peptides’ ability to increase cellular cAMP. Notably, KPV did not reduce neutrophil killing of pathogens but rather enhanced it, a phenotype that distinguishes KPV from classical anti-inflammatory agents that often suppress microbicidal function. This combination of anti-inflammatory, reparative, and antimicrobial effects is a distinctive feature of KPV that has motivated research into its use in models where infection and inflammation coexist.
The 2006 study by Gatti et al. in the Journal of Surgical Research extended the anti-endotoxin research to the disulfide-linked dimer (CKPV)2, showing that this dimer form inhibited TNF-α production in LPS-stimulated human PBMC, reduced circulating TNF-α in LPS-injected rats, and restored net ultrafiltrate in a rat model of LPS-induced peritonitis [12]. (CKPV)2 was more potent than KPV monomer in these assays, providing a rationale for its continued investigation as a research probe.
Stability, Storage, and Handling in the Laboratory
KPV is a small, chemically robust tripeptide that is straightforward to handle in the laboratory:
- Lyophilized form: Stable at -20°C or 2-8°C for long-term research storage, protected from moisture. KPV’s small size and lack of labile side chains (no Cys, no Met, no Trp) make it less prone to oxidative degradation than larger peptides with vulnerable residues.
- Reconstitution: Water, PBS, or dilute acetic acid are standard research reconstitution solvents. KPV is freely water-soluble and does not typically require organic co-solvents.
- Post-reconstitution stability: Aqueous solutions are stable for days to weeks at 2-8°C. For longer-term research storage, aliquot and freeze at -20°C or -80°C. Repeated freeze-thaw cycles should be avoided as a general principle, though KPV is more tolerant than larger peptides.
- Oral formulation research: Because PepT1 is the absorption route of interest, oral research formulations (typically drinking water or gavage) are well established in the published IBD literature [3][4]. Nanoparticle-encapsulated formulations (alginate/chitosan, hyaluronic acid) have been characterized for targeted colonic delivery in research models [5][9].
- Analytical QC: HPLC purity ≥95% and mass spectrometric confirmation of the tripeptide mass (~342 Da free acid, ~341 Da amide) are standard research-grade QC expectations. Purity should be verified from a certificate of analysis.
- Purity considerations: Because KPV is so short, it is possible for synthesis byproducts (deletion sequences, oxidation products, racemized residues) to co-elute with the parent peptide. Researchers should review HPLC and MS data carefully.
Administration-route research in published preclinical literature has included oral, topical (ocular, intracolonic), intraperitoneal, subcutaneous, and nanoparticle-mediated delivery [3][4][5][6][9]. Specific doses and formulations are reported in the primary literature as bibliographic context, not as guidance for human use.
Research Considerations and Limitations
Receptor biology is incompletely characterized. Unlike its parent α-MSH, KPV does not have a cleanly defined high-affinity melanocortin receptor interaction. Its anti-inflammatory effects appear to involve a mix of receptor-dependent (MC3R, possibly others) and receptor-independent (NF-κB, NO, PepT1 uptake) mechanisms [4][8]. Researchers should be cautious about assuming a single mechanism in a new experimental system.
Species and tissue specificity. PepT1 expression, MC1R/MC3R distribution, and NO pathway activity all vary across species and tissues. Extrapolation from rodent IBD research to other inflammation research models should account for these differences.
Dose-response nonlinearity. Several published studies have reported that KPV is active in the nanomolar range in vitro but require higher doses in vivo, consistent with the small peptide’s rapid clearance. The nanoparticle delivery work was motivated in part by this pharmacokinetic limitation [5].
Metabolic stability. Free KPV in plasma is subject to rapid peptidase degradation. The glycomimetic modification research by Songok et al. 2018 explored reductive glycoalkylation of the lysine residue to improve enzymatic stability, with analogs showing proteolytic resistance while retaining some biological activity [11]. This is a useful research lead for investigators interested in extending KPV’s in vivo half-life.
Translational caveats. The majority of published KPV research has been in preclinical cell-culture and rodent models. Human interventional research is limited, and researchers should exercise the standard caution in interpreting translational claims.
Frequently Asked Research Questions
Q1: What is the relationship between KPV and α-MSH?
KPV corresponds to residues 11-13 (C-terminal tripeptide) of α-MSH, which is itself a 13-residue peptide derived from proopiomelanocortin (POMC) by post-translational processing. Full-length α-MSH binds melanocortin receptors (MC1R-MC5R) via the central His-Phe-Arg-Trp core, while KPV lacks this core and retains anti-inflammatory activity through largely receptor-independent mechanisms [1][2][3]. In research settings, KPV offers a way to separate α-MSH-like anti-inflammatory effects from the pigmentary/hormonal effects mediated by MC1R and other classical melanocortin receptors.
Q2: How does KPV enter cells?
In intestinal epithelial cells and immune cells, KPV is taken up by PepT1, a proton-coupled di/tripeptide transporter that is upregulated in inflamed colonic tissue [4]. In airway epithelium, KPV has been reported to undergo nuclear import via importin-α machinery, potentially bypassing the need for a specific surface receptor [8]. The relative contribution of these pathways varies by tissue and experimental context.
Q3: Is KPV orally bioavailable?
In preclinical research models, KPV administered orally (in drinking water or by gavage) has produced measurable anti-inflammatory effects, particularly in IBD research [3][4]. The PepT1-mediated uptake mechanism provides a rational basis for oral delivery to the gastrointestinal tract. For research applications targeting extra-intestinal tissues, alternative routes (topical, subcutaneous, nanoparticle-mediated) have been characterized in the published literature.
Q4: What is (CKPV)2 and how does it relate to KPV?
(CKPV)2 is a disulfide-linked dimer composed of two KPV sequences bridged by Cys-Cys. It has been reported to have greater potency than KPV monomer in anti-endotoxin research assays, including LPS-stimulated TNF-α production in human PBMC and LPS-induced peritonitis in rats [12]. The dimer form is a useful research variant for studies requiring higher potency.
Q5: What are the best in vitro research models for KPV anti-inflammatory research?
For intestinal research, Caco-2 (or Caco2-BBE), HT29-Cl.19A, and RAW 264.7 macrophages are well-established systems [4]. For airway research, 16HBE14o- human bronchial epithelial cells have been characterized [8]. Jurkat T cells have been used for lymphocyte-focused research [4]. Pro-inflammatory stimuli typically include TNF-α, IL-1β, LPS, or IFN-γ, with readouts including NF-κB reporter assays, cytokine ELISAs (IL-8, IL-6, TNF-α), and MAP kinase phosphorylation by Western blot.
References
According to PubMed, the following peer-reviewed articles were used as primary sources for this research overview. DOI links are provided where available.
- Luger TA, Brzoska T. alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 2007;66 Suppl 3:iii52-5. PMID: 17934097. DOI
- Brzoska T, Böhm M, Lügering A, Loser K, Luger TA. Terminal signal: anti-inflammatory effects of α-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Adv Exp Med Biol. 2010;681:107-16. PMID: 21222263. DOI
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-31. PMID: 18092346. DOI
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-78. PMID: 18061177. DOI
- Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843-53.e1-2. PMID: 19909746. DOI
- Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006;83(6):1366-72. PMID: 16965771. DOI
- Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci. 2003;994:133-40. PMID: 12851308. DOI
- Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2):59-73. PMID: 22837805.
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741. DOI
- Cutuli M, Cristiani S, Lipton JM, Catania A. Antimicrobial effects of alpha-MSH peptides. J Leukoc Biol. 2000;67(2):233-9. PMID: 10670585. DOI
- Songok AC, Panta P, Doerrler WT, Macnaughtan MA, Taylor CM. Structural modification of the tripeptide KPV by reductive “glycoalkylation” of the lysine residue. PLoS One. 2018;13(6):e0199686. PMID: 29953505. DOI
- Gatti S, Carlin A, Sordi A, et al. Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions. J Surg Res. 2006;131(2):209-14. PMID: 16413580. DOI
Disclaimer: All products sold by CertaPeptides are intended for laboratory research use only. Not for human or veterinary use. Not for consumption. This article is provided for scientific and educational purposes and does not constitute medical advice, dosing guidance, or an endorsement of any particular use. Researchers are responsible for complying with all applicable institutional, national, and international regulations governing the acquisition, handling, and study of peptide research compounds.